Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Adam_Keeney
|
| gptkbp:focusesOn |
inflammatory diseases
NLRP3 inflammasome inhibitors |
| gptkbp:foundedIn |
2016
|
| gptkbp:founder |
gptkb:Adam_Keeney
|
| gptkbp:hasProductCandidate |
gptkb:NT-0167
NT-0249 NT-0796 |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
NodThera
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:5AM_Ventures
gptkb:F-Prime_Capital gptkb:Epidarex_Capital gptkb:Novo_Holdings gptkb:Sanofi_Ventures |
| gptkbp:therapeuticArea |
autoimmune diseases
metabolic diseases neurological diseases |
| gptkbp:website |
https://www.nodthera.com/
|
| gptkbp:bfsParent |
gptkb:Fine_Structure_Ventures
gptkb:a16z_Bio |
| gptkbp:bfsLayer |
7
|